Literature DB >> 11561605

The diagnosis of pancreatic cancer.

R Brand1.   

Abstract

Despite increasing interest and research on pancreatic cancer, patients with this devastating disease have a very poor prognosis. The principal reason for this grim prognosis is the inability to diagnose the disease at an early, localized, and curable stage. This review is intended to present an overview of our current status on the diagnosis of pancreatic cancer and emphasize recent advances in imaging and tumor markers that are attempting to overcome the challenges of this dreaded disease. Clinical presentation and risk factors for pancreatic cancer are reviewed. Various imaging modalities-including endoscopic and transabdominal ultrasound, ERCP, CT, MRI and PET-are described, with emphasis on their limitations for diagnosing pancreatic cancer at a size that has a significant impact on survival rates. The most promising approach for the early diagnosis of pancreatic adenocarcinoma utilizes tumor markers. Many of the tumor markers investigated over the past 20 years as well as some promising markers under current investigation are reviewed. The combination of serum markers may improve sensitivity and specificity in making the diagnosis of pancreatic adenocarcinoma. We conclude that the current status of imaging and tumor markers does not permit the early diagnosis of an adenocarcinoma of the pancreas. The development of improved early detection methods for pancreatic cancer is essential; however, at the present time it should be limited to high-risk individuals to allow for a better opportunity for success.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11561605

Source DB:  PubMed          Journal:  Cancer J        ISSN: 1528-9117            Impact factor:   3.360


  16 in total

1.  Multiplex targeted proteomic assay for biomarker detection in plasma: a pancreatic cancer biomarker case study.

Authors:  Sheng Pan; Ru Chen; Randall E Brand; Sarah Hawley; Yasuko Tamura; Philip R Gafken; Brian P Milless; David R Goodlett; John Rush; Teresa A Brentnall
Journal:  J Proteome Res       Date:  2012-02-08       Impact factor: 4.466

2.  Advances in counselling and surveillance of patients at risk for pancreatic cancer.

Authors:  Randall E Brand; Markus M Lerch; Wendy S Rubinstein; John P Neoptolemos; David C Whitcomb; Ralph H Hruban; Teresa A Brentnall; Henry T Lynch; Marcia I Canto
Journal:  Gut       Date:  2007-10       Impact factor: 23.059

3.  Proteome analysis of human pancreatic ductal adenocarcinoma tissue using two-dimensional gel electrophoresis and tandem mass spectrometry for identification of disease-related proteins.

Authors:  Rui Tian; Li-Ming Wei; Ren-Yi Qin; Yan Li; Zhi-Yong Du; Wei Xia; Cheng-Jian Shi; Hong Jin
Journal:  Dig Dis Sci       Date:  2007-05-11       Impact factor: 3.199

Review 4.  Hereditary pancreatic cancer: molecular bases and their application in diagnosis and clinical management: a guideline of the TTD group.

Authors:  P Pérez Segura; C Guillén Ponce; T Ramón Y Cajal; R Serrano Blanch; E Aranda
Journal:  Clin Transl Oncol       Date:  2012-07-19       Impact factor: 3.405

5.  Protein alterations associated with pancreatic cancer and chronic pancreatitis found in human plasma using global quantitative proteomics profiling.

Authors:  Sheng Pan; Ru Chen; David A Crispin; Damon May; Tyler Stevens; Martin W McIntosh; Mary P Bronner; Argyrios Ziogas; Hoda Anton-Culver; Teresa A Brentnall
Journal:  J Proteome Res       Date:  2011-03-28       Impact factor: 4.466

6.  Sensitive luciferin derived probes for selective carboxypeptidase activity.

Authors:  Yu-Cheng Chang; Pei-Wen Chao; Ching-Hsuan Tung
Journal:  Bioorg Med Chem Lett       Date:  2011-05-14       Impact factor: 2.823

Review 7.  Pancreatic cancer and the FAMMM syndrome.

Authors:  Henry T Lynch; Ramon M Fusaro; Jane F Lynch; Randall Brand
Journal:  Fam Cancer       Date:  2007-11-09       Impact factor: 2.375

8.  Quantitative proteomics investigation of pancreatic intraepithelial neoplasia.

Authors:  Sheng Pan; Ru Chen; Beth Ann Reimel; David A Crispin; Hamid Mirzaei; Kelly Cooke; Joshua F Coleman; Zhaoli Lane; Mary P Bronner; David R Goodlett; Martin W McIntosh; William Traverso; Ruedi Aebersold; Teresa A Brentnall
Journal:  Electrophoresis       Date:  2009-04       Impact factor: 3.535

9.  Proteomics studies of pancreatic cancer.

Authors:  Ru Chen; Sheng Pan; Ruedi Aebersold; Teresa A Brentnall
Journal:  Proteomics Clin Appl       Date:  2007       Impact factor: 3.494

10.  CEACAM6 is a determinant of pancreatic adenocarcinoma cellular invasiveness.

Authors:  M S Duxbury; H Ito; E Benoit; S W Ashley; E E Whang
Journal:  Br J Cancer       Date:  2004-10-04       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.